期刊
NATURE BIOMEDICAL ENGINEERING
卷 6, 期 3, 页码 267-+出版社
NATURE PORTFOLIO
DOI: 10.1038/s41551-022-00860-y
关键词
-
资金
- NIH [R01-CA215719, U54-CA137788, U54-CA132378, P30-CA008748, R01-GM114167, 201708320366]
- National Science Foundation CAREER Award [1752506]
- Honorable Tina Brozman Foundation for Ovarian Cancer Research
- Tina Brozman Ovarian Cancer Research Consortium 2.0
- Kelly Auletta Fund for Ovarian Cancer Research
- American Cancer Society Research Scholar Grant [GC230452]
- Pershing Square Sohn Cancer Research Alliance
- Expect Miracles Foundation - Financial Services Against Cancer
- Experimental Therapeutics Center
- Commonwealth Foundation for Cancer Research
- China Scholarships Council (CSC) [201708320366]
- University of Maryland
- NIST
- Dean's Fellowship at Lehigh University
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [1752506] Funding Source: National Science Foundation
Ovarian cancer can be accurately predicted using a disease fingerprint obtained through machine learning from the spectra of near-infrared fluorescence emissions of a carbon nanotube sensor array.
Ovarian cancer can be predicted with high sensitivity and specificity via a fingerprint obtained, via machine learning, from near-infrared fluorescence emissions of an array of carbon nanotube sensors in serum samples. Serum biomarkers are often insufficiently sensitive or specific to facilitate cancer screening or diagnostic testing. In ovarian cancer, the few established serum biomarkers are highly specific, yet insufficiently sensitive to detect early-stage disease and to impact the mortality rates of patients with this cancer. Here we show that a 'disease fingerprint' acquired via machine learning from the spectra of near-infrared fluorescence emissions of an array of carbon nanotubes functionalized with quantum defects detects high-grade serous ovarian carcinoma in serum samples from symptomatic individuals with 87% sensitivity at 98% specificity (compared with 84% sensitivity at 98% specificity for the current best clinical screening test, which uses measurements of cancer antigen 125 and transvaginal ultrasonography). We used 269 serum samples to train and validate several machine-learning classifiers for the discrimination of patients with ovarian cancer from those with other diseases and from healthy individuals. The predictive values of the best classifier could not be attained via known protein biomarkers, suggesting that the array of nanotube sensors responds to unidentified serum biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据